Watch MLTX. Know when insiders buy.
One email the day a filing lands. Free.
MLTX
MoonLake Immunotherapeutics
12.39
+0.04 +0.32%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
39
FLAG · shorts 39
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.1BP/E —DIV YIELD —FCF YIELD -21.35%REV TTM —NET INCOME −$263.7MNET CASH $378.4M52W 6.24 – 61.99SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$61.7M | −$61.8M | — | -0.84 | −$55.6M | $0 | −$55.6M | Aug 10 |
| Q1 2026 · Mar 31 | — | — | — | −$70M | −$69.7M | — | -0.98 | −$66.3M | $0 | −$66.3M | May 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$65.2M | −$62.4M | — | -0.92 | −$58.8M | $0 | −$58.8M | Feb 25 |
| Q3 2025 · Sep 30 | — | — | — | −$71.4M | −$69.7M | — | -1.10 | −$44.5M | $0 | −$44.5M | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$60.7M | −$55.2M | — | -0.87 | −$54.5M | $0 | −$54.5M | Aug 10 |
| Q1 2025 · Mar 31 | — | — | — | −$47.5M | −$39.9M | — | -0.63 | −$38.1M | $35K | −$38.2M | May 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$49.6M | −$45.6M | — | -0.72 | −$48.5M | $176K | −$48.6M | Feb 25 |
| Q3 2024 · Sep 30 | — | — | — | −$43.1M | −$35.4M | — | -0.56 | −$25.3M | $132K | −$25.4M | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$30.6M | −$24.3M | — | -0.39 | −$27.9M | $0 | −$27.9M | Aug 5 |
| Q1 2024 · Mar 31 | — | — | — | −$19.8M | −$13.7M | — | -0.22 | −$14.9M | $212K | −$15.2M | May 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$15M | −$7.4M | — | -0.10 | −$12.3M | $284K | −$12.6M | Feb 25 |
| Q3 2023 · Sep 30 | — | — | — | −$13M | −$9.4M | — | -0.18 | −$9.3M | $0 | −$9.3M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$244.8M | −$227.3M | — | -3.53 | −$196M | $35K | −$196M | — | — |
| FY2024 · to Dec 31 | — | — | −$143.1M | −$118.9M | — | -1.89 | −$116.6M | $520K | −$117.1M | $50 | — |
| FY2023 · to Dec 31 | — | — | −$54.1M | −$36M | — | -0.73 | −$42.8M | $284K | −$43.1M | $0 | — |
| FY2022 · to Dec 31 | — | — | −$65.1M | −$50M | — | -1.70 | −$55.9M | $16K | −$55.9M | $0 | — |
| FY2021 · to Dec 31 | — | — | −$4.6M | −$4.5M | — | -0.31 | −$611K | — | — | — | — |
Every number comes from MoonLake Immunotherapeutics's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.